Advancing Pharmacoequity in Atrial Fibrillation-The Case for Direct Oral Anticoagulants.
Publication
, Journal Article
Boursiquot, BC; Jackson, LR; Essien, UR
Published in: JAMA Netw Open
May 1, 2024
Duke Scholars
Published In
JAMA Netw Open
DOI
EISSN
2574-3805
Publication Date
May 1, 2024
Volume
7
Issue
5
Start / End Page
e249403
Location
United States
Related Subject Headings
- Stroke
- Humans
- Factor Xa Inhibitors
- Atrial Fibrillation
- Anticoagulants
- Administration, Oral
- 42 Health sciences
- 32 Biomedical and clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Boursiquot, B. C., Jackson, L. R., & Essien, U. R. (2024). Advancing Pharmacoequity in Atrial Fibrillation-The Case for Direct Oral Anticoagulants. JAMA Netw Open, 7(5), e249403. https://doi.org/10.1001/jamanetworkopen.2024.9403
Boursiquot, Brian C., Larry R. Jackson, and Utibe R. Essien. “Advancing Pharmacoequity in Atrial Fibrillation-The Case for Direct Oral Anticoagulants.” JAMA Netw Open 7, no. 5 (May 1, 2024): e249403. https://doi.org/10.1001/jamanetworkopen.2024.9403.
Boursiquot BC, Jackson LR, Essien UR. Advancing Pharmacoequity in Atrial Fibrillation-The Case for Direct Oral Anticoagulants. JAMA Netw Open. 2024 May 1;7(5):e249403.
Boursiquot, Brian C., et al. “Advancing Pharmacoequity in Atrial Fibrillation-The Case for Direct Oral Anticoagulants.” JAMA Netw Open, vol. 7, no. 5, May 2024, p. e249403. Pubmed, doi:10.1001/jamanetworkopen.2024.9403.
Boursiquot BC, Jackson LR, Essien UR. Advancing Pharmacoequity in Atrial Fibrillation-The Case for Direct Oral Anticoagulants. JAMA Netw Open. 2024 May 1;7(5):e249403.
Published In
JAMA Netw Open
DOI
EISSN
2574-3805
Publication Date
May 1, 2024
Volume
7
Issue
5
Start / End Page
e249403
Location
United States
Related Subject Headings
- Stroke
- Humans
- Factor Xa Inhibitors
- Atrial Fibrillation
- Anticoagulants
- Administration, Oral
- 42 Health sciences
- 32 Biomedical and clinical sciences